Page 17 - Teddy Whiley News Today

ANGLE plc: Angle PLC- Ovarian Cancer Study Patient Enrolment Completed Headline results from the Study expected in Q4 2021 Study designed to support launch of an ovarian cancer test from ANGLEs clinical laboratories in the United States and the UK GUILDFORD, SURREY, UK / ACCESSWIRE / April 26, 2021 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that its 200 patient ovarian cancer clinical verification study ("the Study") has completed patient e...

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any natio...

About ANGLE plc   www.angleplc.com   ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLEs proven patent protected platforms include a circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.   ANGLEs cell separation technology is called the Parsortix® system, and it enables a liquid biopsy (a simple blood te...

ANGLE plc: Angle PLC Announces Notice of Preliminary Results and Webcast GUILDFORD, SURREY / ACCESSWIRE / April 15, 2021 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, will be releasing its preliminary results for the year ended 31 December 2020 on Thursday 29 April 2021. A virtual meeting and webcast for analysts will be held at 10:00 am BST on Thursday 29 April 2021. If you wish to attend, please register in advance and log on to the webcast approximately 5 minutes ...

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any natio...

  Avacta Group is developing novel cancer immunotherapies and powerful diagnostics based on its two proprietary platforms - Affimer® biologics and pre|CISION™ tumour targeted chemotherapies.   The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets, such as diagnostics and therapeutics, worth in excess of $100bn. Affimer technology has been designed to address many of...

DJ Eve Sleep plc: Notice of Investor Presentation Eve Sleep plc (EVE) Eve Sleep plc: Notice of Investor Presentation 11-March-2021 / 10:05 GMT/BST Dissemination of a Regulatory Announcement, transmitted

About ANGLE plc www.angleplc.com   ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLEs proven patent protected platforms include a circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.   ANGLEs cell separation technology is called the Parsortix ® system, and it enables a liquid biopsy (a simple b...

Press release content from Accesswire. The AP news staff was not involved in its creation. Angle PLC Announces Parsortix-Harvested CTCs Uncover Novel Biomarker February 18, 2021 GMT Parsortix system able to harvest difficult-to-detect mesenchymal CTCs Metastatic biomarker Cyr61 found by researchers in 40% of breast cancer CTCs may be a novel therapeutic target in treating drug-resistant breast cancers GUILDFORD, SURREY / ACCESSWIRE / February 18, 2021 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-...

Investegate announcements from Omega Diagnostics Gp, Director/PDMR Shareholding